Why Doesn't Codeine Work for Me? The CYP2D6 Explanation

If you have taken codeine for pain and felt like it did absolutely nothing — not even mild relief — you are not imagining it. Depending on population, up to about 5% of people are CYP2D6 poor metabolizers, meaning their body cannot convert codeine into morphine, the molecule that actually relieves pain. Codeine itself is essentially inactive. Without this conversion, it is as effective as a placebo. If you are unfamiliar with what poor metabolizer status means, it is worth understanding — it affects far more than just codeine.

Intermediate metabolizers — who convert some codeine, but not enough for full pain relief at standard doses — account for up to about 11%, again depending on population. Together, a meaningful minority of people get a suboptimal response from codeine for genetic reasons alone.

How Codeine Works (and Why It Fails)

Codeine is a prodrug — it must be converted into morphine by your CYP2D6 enzyme before it can relieve pain. If your CYP2D6 enzyme has reduced or absent function, this conversion does not happen effectively.

This is not a question of tolerance, dose, or willpower. It is a genetic constraint: your body physically cannot produce enough of the active compound from the inactive one.

The same applies to tramadol, which also requires CYP2D6 activation. If codeine does not work for you, tramadol may not work either — for the exact same reason.

The Opposite Problem: Codeine That Is Too Strong

On the other end of the spectrum, about 1–2% of people are CYP2D6 ultrarapid metabolizers. Their bodies convert codeine into morphine too quickly, producing higher-than-expected morphine levels from a standard dose. This can cause serious side effects including excessive sedation and respiratory depression. CPIC clinical guidelines recommend avoiding codeine entirely in ultrarapid metabolizers.

What Raw DNA Data Can (and Can't) Tell You About CYP2D6

If you have 23andMe, AncestryDNA, or similar raw DNA data, your file contains some of the SNPs that define common CYP2D6 star alleles (*4, *10, *41). What it does not contain is the structural picture: gene deletions (*5), duplications, and CYP2D6/CYP2D7 hybrid alleles are invisible to a genotyping array — and those are exactly what separate a poor metabolizer from an ultrarapid one.

So a CYP2D6 metabolizer status computed from raw data alone is not reliable enough to guide a codeine decision. DecodeMyBio does not call CYP2D6 from your raw data. Rather than guess, we tell you the truth: CYP2D6 needs a specialized caller that a consumer array does not provide, and we will never invent a result it cannot support. If a pain-management decision hinges on your CYP2D6 status, ask your prescriber about clinical-grade pharmacogenomic testing that includes copy-number analysis. The full gene guide is at CYP2D6.

What DecodeMyBio's Pain & Anesthesia results do cover is OPRM1 (opioid receptor sensitivity), COMT (pain perception), BDNF (pain modulation), and ANKK1 — explaining how those genes shape your response to pain medication in practice. And Decode maps CPIC guidance for the pharmacogenes an array can support, including CYP2C19.

What to Do If Codeine Doesn't Work for You

If you suspect you are a CYP2D6 poor metabolizer:

• Do not increase the dose. More codeine will not produce more morphine if your enzyme cannot convert it.
• Tell your prescriber. Alternative pain medications that do not require CYP2D6 activation (such as morphine itself, oxymorphone, or non-opioid options) may be more effective.
• Consider pharmacogenomic testing. A one-time genetic result that explains codeine non-response also applies to tramadol, antidepressants, and other CYP2D6-metabolized drugs. See the full list of CYP2D6 poor metabolizer symptoms and affected medications.

What to Do Next

1. Download your raw DNA data if you haven't already — see our upload guide for step-by-step instructions.
2. Get your Pain & Anesthesia results — they cover OPRM1, COMT, BDNF, and ANKK1. They do not include a CYP2D6 metabolizer status, which a genotyping array cannot support. Learn more →
3. Share your results with your doctor — your results include a provider-ready summary designed for prescriber use. See how it works →

Clinical Evidence

CYP2D6-codeine is one of the strongest drug-gene interactions in clinical pharmacogenomics. CPIC (Clinical Pharmacogenetics Implementation Consortium) classifies it as Level A — the highest evidence tier, the same standard used by hospitals for prescribing decisions. The guideline recommends avoiding codeine in poor metabolizers and ultrarapid metabolizers (PMID: 24458010).